Abstract
BackgroundCoeliac disease (CD) is an enteropathy characterized by an aberrant immune response to cereal-gluten proteins. Although gluten peptides and microorganisms activate similar pro-inflammatory pathways, the role the intestinal microbiota may play in this disorder is unknown. The purpose of this study was to assess whether the faecal microbiota of coeliac patients could contribute to the pro-inflammatory milieu characteristic of CD and the possible benefits of bifidobacteria.MethodsThe effect of faeces of 26 CD patients with active disease (mean age 5.5 years, range 2.1–12.0 years), 18 symptom-free coeliac disease (SFCD) patients (mean age 5.5 years, range 1.0–12.3 years) on a gluten-free diet for 1–2 years; and 20 healthy children (mean age 5.3 years, range 1.8–10.8 years) on induction of cytokine production and surface antigen expression in peripheral blood mononuclear cells (PBMCs) were determined. The possible regulatory roles of Bifidobacterium longum ES1 and B. bifidum ES2 co-incubated with faecal samples were also assessed in vitro.ResultsFaeces of both active CD and SFCD patients, representing an imbalanced microbiota, significantly increased TNF-α production and CD86 expression in PBMCs, while decreased IL-10 cytokine production and CD4 expression compared with control samples. Active CD-patient samples also induced significantly higher IFN-γ production compared with controls. However, Bifidobacterium strains suppressed the pro-inflammatory cytokine pattern induced by the large intestinal content of CD patients and increased IL-10 production. Cytokine effects induced by faecal microbiota seemed to be mediated by the NFκB pathway.ConclusionThe intestinal microbiota of CD patients could contribute to the Th1 pro-inflammatory milieu characteristic of the disease, while B. longum ES1 and B. bifidum ES2 could reverse these deleterious effects. These findings hold future perspectives of interest in CD therapy.
Highlights
Coeliac disease (CD) is an enteropathy characterized by an aberrant immune response to cereal-gluten proteins
The intestinal microbiota of CD patients could contribute to the T helper 1 (Th1) proinflammatory milieu characteristic of the disease, while B. longum ES1 and B. bifidum ES2 could reverse these deleterious effects
A Th1 response dominated by high levels of interferon gamma (IFN-γ) has been reported in the small intestine of untreated CD patients and in the mucosa of treated patients, following culture in vitro with gliadin [20] as well as in intraepithelial lymphocytes isolated from untreated coeliac mucosal samples [19,21]
Summary
Coeliac disease (CD) is an enteropathy characterized by an aberrant immune response to cereal-gluten proteins. The intestinal inflammatory milieu characteristic of CD patients depends on the pro-inflammatory cytokines produced during abnormal response to gluten, involving several intracellular signal transduction pathways, such as nuclear factor kappa (NFκ) B, the interferon regulatory factor (IRF)-1 and signal transducer and activator of transcription [4,5,6]. Increased production of pro-inflammatory cytokines by cells of the innate immune system could favour the recruitment of lymphocytes into the lamina propria and epithelium, contributing to full expression of the disease [6]. These pathological mechanisms lead to typical CD lesions, characterized by a massive intraepithelial infiltration of lymphocytes, crypt hyperplasia and villous atrophy [1]. Poor compliance and associated complications of the disease demand alternative therapeutic strategies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.